Flying The Web For News.
  • New Year's
    New Year's
  • Career Exam Study
    Career Exam Study
  • 2024 Presidential Election
    2024 Presidential Election
  • E-commerce Guide
    E-commerce Guide
  • Dropshipping Guide
    Dropshipping Guide
  • Microsoft Exam
    Microsoft Exam
  • IT Career News
    IT Career News
+ Larger Font | - Smaller Font
Share

Globe NewsWire News Distribution Service


LOS ANGELES, Oct. 28, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR) investors of a class action representing investors that bought securities between May 17, 2022, and July 19, 2024, inclusive (the "Class Period"). Allarity investors have until November 12, 2024 to file a lead plaintiff motion.


Posted: 2024-10-29 03:29:00

Get Full News Story On GlobeNewsWire Press Release Service



Listen to this article. Speaker link opens in a new window.
Text To Speech BETA Test Version.



Related News Stories From The Web And More

Related Bing News Search Results

Press Release: Allarity Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. November 12, 2024 Deadline to file Lead Plaintiff Motion. - Newscast

Stenoparib by Allarity Therapeutics for Endometrial Cancer: Likelihood of Approval

Mon, 30 Dec 2024 10:23:00 GMT Stenoparib is under clinical development by Allarity Therapeutics and currently in Phase I for Endometrial Cancer.

Applied Therapeutics, Inc. Being Investigated on Behalf of Applied Therapeutics, Inc. Investors. Contact Levi & Korsinsky For Details.

Thu, 12 Dec 2024 02:15:00 GMT NEW YORK, NY / ACCESSWIRE / December 12, 2024 / Levi & Korsinsky notifies investors that it ... federal securities laws. Applied Therapeutics issued a press release on November 27, 2024 ...

Allarity Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your ...

Thu, 05 Dec 2024 16:01:00 GMT The Portnoy Law Firm advises Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ: ALLR) investors of a class action representing investors that bought securities between May 17 ...

Allarity Therapeutics Provides Corporate Update in Recent Press Release

Wed, 20 Nov 2024 16:00:00 GMT The detailed insights from the corporate update can be found in the press release ... accessible for investors and stakeholders. In conjunction with this announcement, Allarity Therapeutics ...

Allarity Therapeutics Reports Key Progress in Phase 2 Stenoparib Trial and Strategic Corporate Advancements

Mon, 18 Nov 2024 05:00:00 GMT Strong Financial Position Supports Advancement of Stenoparib Program With a cash balance of $18.5 million as of September 30, 2024, Allarity Therapeutics is well-positioned to advance its clinical ...


Blow Us A Whistle